The 2013 Annual Report for The Leukemia & Lymphoma Society has been released. In this series of blogs, a number of key advancements and developments will be highlighted. This report is an in-depth look at how your fundraising dollars are being spent and the medical breakthroughs and partnerships you are so crucial in creating.
The Leukemia & Lymphoma Society (LLS) is well positioned to align the key players in the ecosystem of cancer innovation. This has led to new and groundbreaking partnerships:
LLS's Therapy Acceleration Program added many new partners from the biopharmaceutical industry and academic institutions. One of the most important was the Knight cancer Institute at Oregon Health & Science University (OHSU). The Beat AML initiative, led by Brian Druker, MD, includes major technology companies like Intel, which provides big data computing technology, and Illumina, which provides advanced genetic sequencing. The goal is to identify the many mutations that drive acute myeloid leukemia and identify drugs that can target these mutations.
In July 2013, LLS announced a partnership with John Hopkins University School of Medicine to advance a novel immunotherapy for patients with poor prognosis myeloma. Under the leadership of Ivan Borrello, MD, researchers are testing a method using immune system T-cells that are specifically trained to recognize and kill myeloma cells. The approach shows promise for patients with other blood cancers as well.
In June 2013, Dana-Farber Cancer Institute joined LLS to establish clinical testing of innovative blood cancer therapies in community oncology settings across the country.
No comments:
Post a Comment